M von Eynatten1,2, P M Lepper3, D Liu4, K Lang5, M Baumann4, P P Nawroth6, A Bierhaus6, K A Dugi6, U Heemann4, B Allolio5, P M Humpert6. 1. Department of Nephrology, Technical University Munich, Ismaningerstr. 22, 81675, Munich, Germany. maximilian.eynatten@lrz.tum.de. 2. Department of Medicine I, Wuerzburg University, Wuerzburg, Germany. maximilian.eynatten@lrz.tum.de. 3. Department of Intensive Care Medicine, University of Bern (Inselspital), Bern, Switzerland. 4. Department of Nephrology, Technical University Munich, Ismaningerstr. 22, 81675, Munich, Germany. 5. Department of Medicine I, Wuerzburg University, Wuerzburg, Germany. 6. Department of Medicine I and Clinical Chemistry, Heidelberg University, Heidelberg, Germany.
Abstract
AIMS/HYPOTHESIS: Retinol-binding protein 4 (RBP4) has recently been reported to be associated with insulin resistance and the metabolic syndrome. This study tested the hypothesis that RBP4 is a marker of insulin resistance and the metabolic syndrome in patients with type 2 diabetes or coronary artery disease (CAD) or in non-diabetic control subjects without CAD. METHODS: Serum RBP4 was measured in 365 men (126 with type 2 diabetes, 143 with CAD and 96 control subjects) and correlated with the homeostasis model assessment of insulin resistance index (HOMA-IR), components of the metabolic syndrome and lipoprotein metabolism. RBP4 was detected by ELISA and validated by quantitative Western blotting. RESULTS: RBP4 concentrations detected by ELISA were shown to be strongly associated with the results gained in quantitative Western blots. There were no associations of RBP4 with HOMA-IR or HbA(1c) in any of the groups studied. In patients with type 2 diabetes there were significant positive correlations of RBP4 with total cholesterol, LDL-cholesterol, VLDL-cholesterol, plasma triacylglycerol and hepatic lipase activity. In patients with CAD, there were significant associations of RBP4 with VLDL-cholesterol, plasma triacylglycerol and hepatic lipase activity, while non-diabetic control subjects without CAD showed positive correlations of RBP4 with VLDL-cholesterol and plasma triacylglycerol. CONCLUSIONS/ INTERPRETATION: RBP4 does not seem to be a valuable marker for identification of the metabolic syndrome or insulin resistance in male patients with type 2 diabetes or CAD. Independent associations of RBP4 with pro-atherogenic lipoproteins and enzymes of lipoprotein metabolism indicate a possible role of RBP4 in lipid metabolism.
AIMS/HYPOTHESIS: Retinol-binding protein 4 (RBP4) has recently been reported to be associated with insulin resistance and the metabolic syndrome. This study tested the hypothesis that RBP4 is a marker of insulin resistance and the metabolic syndrome in patients with type 2 diabetes or coronary artery disease (CAD) or in non-diabetic control subjects without CAD. METHODS: Serum RBP4 was measured in 365 men (126 with type 2 diabetes, 143 with CAD and 96 control subjects) and correlated with the homeostasis model assessment of insulin resistance index (HOMA-IR), components of the metabolic syndrome and lipoprotein metabolism. RBP4 was detected by ELISA and validated by quantitative Western blotting. RESULTS:RBP4 concentrations detected by ELISA were shown to be strongly associated with the results gained in quantitative Western blots. There were no associations of RBP4 with HOMA-IR or HbA(1c) in any of the groups studied. In patients with type 2 diabetes there were significant positive correlations of RBP4 with total cholesterol, LDL-cholesterol, VLDL-cholesterol, plasma triacylglycerol and hepatic lipase activity. In patients with CAD, there were significant associations of RBP4 with VLDL-cholesterol, plasma triacylglycerol and hepatic lipase activity, while non-diabetic control subjects without CAD showed positive correlations of RBP4 with VLDL-cholesterol and plasma triacylglycerol. CONCLUSIONS/ INTERPRETATION:RBP4 does not seem to be a valuable marker for identification of the metabolic syndrome or insulin resistance in male patients with type 2 diabetes or CAD. Independent associations of RBP4 with pro-atherogenic lipoproteins and enzymes of lipoprotein metabolism indicate a possible role of RBP4 in lipid metabolism.
Authors: Gabriel I Uwaifo; Erica M Fallon; Jeff Chin; Jane Elberg; Shamik J Parikh; Jack A Yanovski Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: Timothy E Graham; Qin Yang; Matthias Blüher; Ann Hammarstedt; Theodore P Ciaraldi; Robert R Henry; Christopher J Wason; Andreas Oberbach; Per-Anders Jansson; Ulf Smith; Barbara B Kahn Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245
Authors: Jochen G Schneider; Maximilian von Eynatten; Stephan Schiekofer; Peter P Nawroth; Klaus A Dugi Journal: Diabetes Care Date: 2005-09 Impact factor: 19.112
Authors: Jürgen Janke; Stefan Engeli; Michael Boschmann; Frauke Adams; Jana Böhnke; Friedrich C Luft; Arya M Sharma; Jens Jordan Journal: Diabetes Date: 2006-10 Impact factor: 9.461
Authors: N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels Journal: J Clin Invest Date: 1998-08-01 Impact factor: 14.808
Authors: Qi Sun; Urban A Kiernan; Ling Shi; David A Phillips; Barbara B Kahn; Frank B Hu; Joann E Manson; Christine M Albert; Kathryn M Rexrode Journal: Circulation Date: 2013-04-12 Impact factor: 29.690
Authors: Dejene F Abetew; Chunfang Qiu; Neway G Fida; Michal Dishi; Karin Hevner; Michelle A Williams; Daniel A Enquobahrie Journal: Diabetes Res Clin Pract Date: 2012-11-13 Impact factor: 5.602